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C-reactive proteinAbstract Inﬂammation is widely considered to be an important contributing factor of the patho-
physiology of coronary heart disease (CHD), and the inﬂammatory cascade is particularly impor-
tant in the atherosclerotic process. In consideration of the important role that inﬂammatory
processes play in CHD, recent work has been focused on whether biomarkers of inﬂammation
may help to improve risk stratiﬁcation and identify patient groups who might beneﬁt from partic-
ular treatment strategies. Of these biomarkers, C-reactive protein (CRP) has emerged as one of the
most important novel inﬂammatory markers. CRP an acute phase protein is synthesized by hepa-
tocytes in response to proinﬂammatory cytokines, in particular interleukin-6. Many large-scale pro-
spective studies demonstrate that CRP strongly and independently predicts adverse cardiovascular
events, including myocardial infarction, ischemic stroke, and sudden cardiac death in individuals
both with and without overt CHD. CRP is believed to be both a marker and a mediator of athero-
sclerosis and CHD. CRP plays a pivotal role in many aspects of atherogenesis including, activation
of complement pathway, lipids uptake by macrophage, release of proinﬂammatory cytokines,
induces the expression of tissue factor in monocytes, promotes the endothelial dysfunction and
inhibits nitric oxide production. The commercial availability of CRP high sensitive assays has made
screening for this marker simple, reliable, and reproducible and can be used as a clinical guide to
diagnosis, management, and prognosis of CHD.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
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Cardiovascular diseases (CVDs) are the leading cause of
mortality and morbidity all over the world, including India.
CVD encompasses coronary heart disease (CHD), as well
as congestive heart failure, stroke, peripheral artery disease,
carotid artery disease, and aortoiliac disease.1 CHD, also
known as coronary artery disease, is the narrowing of the
blood vessels, as a result of atherosclerosis that supply blood
and oxygen to the heart. CHD can lead to unstable angina,
myocardial infarction (MI), and heart failure.2 According
to World Health Organization (WHO) estimates, 17.3 million
people died from CVDs in 2008, representing 30% of all glo-
bal deaths. Of these deaths, an estimated 7.3 million were due
to CHD and 6.2 million were due to stroke.3 CHD is
decreasing in many developed countries (due to improved
prevention {in particular reduced cigarette smoking among
adults, and lower average levels of blood pressure and blood
cholesterol}, diagnosis, and treatment), but is increasing in
developing and transitional countries, partly as a result of
increasing longevity, urbanization, and lifestyle changes. In
developed countries, CHD is predicted to raise 30–60%
between 1990 and 2020. In developing countries, rates are
predicted to increase by 120% in women and 137% in men
from 1990 to 2020.4
During the past decades a great deal of knowledge concern-
ing the pathophysiology of CHD has been achieved, and age
(older than 40 years for men, 45 years for women), male sex,
family history of CHD, smoking, hypertension, diabetes, obes-
ity, high total cholesterol, low high density lipoprotein choles-
terol (HDL-C), high low density lipoprotein cholesterol (LDL-
C), high triglycerides, low physical activity, and accumulation
of abdominal fat are some of the major risk factors.5 However,
despite identiﬁcation of important risk factors, CHD remains
the leading cause of death worldwide. Up to half of all events
associated with CHD are reported to occur in apparently
healthy individuals who have few or none of the traditional
risk factors, including dyslipidemia. As a result, attention has
increasingly turned to the role of other factors, such as inﬂam-
mation, in the development of atherosclerosis and CHD.6Atherosclerosis, the underlying pathology responsible for
CHD, is an inﬂammatory disease. Recent observations suggest
that the atherosclerotic process is characterized by a low-grade
inﬂammation altering the endothelium of the coronary arteries
and is associated with an increase level in markers of inﬂam-
mation such as acute phase proteins and cytokines. Cumula-
tive evidence indicates that inﬂammation, at both focal and
systemic levels, plays a key role in destabilization and rupture
of atherosclerotic plaques, leading to acute cardiovascular
events.7 In consideration of the important role that inﬂamma-
tory processes play in determining plaque stability, recent
work has focused on whether biomarkers of inﬂammation
may help to improve risk stratiﬁcation and identify patient
groups who might beneﬁt from particular treatment strategies.
Among them, C-reactive protein (CRP), a prototype marker of
the inﬂammatory process, is the most studied both as a causal
factor and in the prediction of CHD.8
CRP is the forerunner in the hunt for inﬂammatory mark-
ers and is subject to intensive research in numerous studies
worldwide. Unlike other markers of inﬂammation, CRP levels
are stable over long periods, have no diurnal variation, can be
measured inexpensively with available high-sensitivity assays,
and have shown speciﬁcity in terms of predicting the risk of
CHD.9 CRP may have a role in the genesis of atherosclerotic
lesion, since it reduces the expression of nitric oxide (NO) syn-
thase and prostacyclin synthase, and binds LDL-C and pro-
motes its uptake by macrophages, a key step in
atherogenesis. CRP also up-regulates the expression of adhe-
sion molecules on endothelial cell (EC). All these phenomena
are associated with atherogenesis.10 Multiple prospective
cohort studies have established that increased CRP levels are
associated with increased CHD risk in both genders, across a
wide age range, and in primary as well as secondary prevention
settings. These ﬁndings have been consistent in different pop-
ulations with diverse ethnic backgrounds and in diverse clinical
settings, and they have predicted risk of a variety of cardiovas-
cular outcomes, including incident acute myocardial infarction
(AMI), stroke, sudden cardiac death, peripheral artery disease
and also incident diabetes and new onset hypertension. CRP
levels have also been shown to predict risk of both recurrent
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angina, those undergoing percutaneous angioplasty, and those
presenting to emergency rooms with acute coronary syndrome
(ACS).7,11
2. Inﬂammation and atherosclerosis
Atherosclerosis is the most common pathological process that
leads to CHD, a disease of large- and medium-sized arteries
that is characterized by a formation of atherosclerotic plaques
consisting of necrotic cores, calciﬁed regions, accumulated
modiﬁed lipids, inﬂamed smooth muscle cells (SMCs), ECs,
leukocytes, and foam cells.12 The word atherosclerosis comes
from the Greek words ‘‘Athero’’ means gruel and corresponds
to the necrotic core at the base of the atherosclerotic plaque,
whereas ‘‘sclerosis’’ means hardening or induration, and corre-
sponds to the ﬁbrotic cap at the luminal edge of the plaque,
and reﬂects quite well the macroscopic morphology of an ath-
erosclerotic lesion, yellow-white thickening of the vessel wall
with a hard ﬁbrous cap in advanced lesion. Despite the ﬁrst
description of inﬂammation in coronary atherosclerosis
200 years back, it is only recently that there has been a wide
acceptance of the role of inﬂammation in the pathogenesis of
atherosclerosis and destabilization of the coronary artery
plaque.10 In 1999, Russel Ross was the ﬁrst, who published
that atherosclerosis is an inﬂammatory disease.13 The
‘‘response to injury’’ theory on the pathophysiology of athero-
sclerosis is best acknowledged nowadays.
Atherosclerosis is characterized by a complex multifactorial
pathophysiology. Inﬂammation in the vessel wall is now con-
sidered to play an essential role in the initiation, progression
and the ﬁnal steps of atherosclerosis, namely plaque destabili-
zation and eventually plaque rupture. Histologically athero-
matous plaques obtained at autopsy have demonstrated the
presence of inﬂammatory mononuclear cells with foci of
monocytes, macrophages and T lymphocytes in the arterial
wall. Anatomically, the most common site of plaque rupture
in ACS appears to occur in the shoulder region, where inﬂam-
matory cells are most prominent and might serve to compro-
mise the integrity of the surrounding connective tissue. From
a pathological point of view, all stages of the atherosclerotic
process, from its initiation to plaque rupture, might be consid-
ered an inﬂammatory response to injury and endothelial dys-
function. Damage to the endothelial wall triggers a cascade
of events that modulates the inﬂammatory response, leading
to the recruitment of white blood cells into the blood vessel
wall, where they give rise to abnormal foam cells and initiate
the development of atherosclerotic lesions.14
3. Pathophysiology of atherosclerosis
The endothelium is an active monolayer of cells lining the
lumen of the vessels, separating the vascular wall from the cir-
culating blood. Under normal conditions, the ECs of the arte-
rial wall resist adhesion and aggregation of leukocytes and
promote ﬁbrinolysis. When activated by stimuli such as hyper-
tension, smoking, an unhealthy diet, obesity, insulin resistance,
inﬂammation or other types of injuries, the ECs express a ser-
ies of adhesion molecules that selectively recruit various classes
of leukocytes. Blood monocytes, the most numerous of the
inﬂammatory cells that populate plaques, adhere to thedysfunctional endothelial surface by binding to leukocyte
adhesion molecules not expressed by normal ECs, but induced
by mediators associated with risk factors such as proinﬂamma-
tory cytokines, angiotensin (AT) II, and oxidized lipoproteins.
Once the monocytes adhere to the activated endothelium, pro-
inﬂammatory proteins known as chemokines provide a chemo-
tactic stimulus that induces them to enter the intima. Within
the intima, the monocytes mature into macrophages, which
express scavenger receptors that allow them to engulf modiﬁed
lipoprotein particles. The cytoplasm becomes engorged with
lipid particles, giving the macrophages the typical microscopic
frothy appearance of the foam cells found in atherosclerotic
lesions.15–17
At the same time, other inﬂammatory mediators, including
activated T cells and mast cells, also attach themselves to the
endothelium. Activation of macrophages, T lymphocytes,
and SMCs leads to the release of additional mediators, includ-
ing adhesion molecules, cytokines, chemokines, and growth
factors, all of which play important roles in atherogenesis.
All of these inﬂammatory cells eventually contribute to the for-
mation of the atheromatous lesion, which consists of a lipid
pool protected by a ﬁbrous cap.18 Over time the plaque attract
deposits of calcium; calciﬁcation of the artery is an important
marker for the development of atherosclerosis. Finally, endo-
thelium-derived NO, a vasoactive molecule that helps to main-
tain vascular tone, is reduced at the site of vascular injury.
Decreased NO production is implicated in the clinical course
of all known CVD. NO has a number of intracellular effects
that lead to vasorelaxation, endothelial regeneration, inhibi-
tion of leukocyte chemotaxis, and platelet adhesion and aggre-
gation. Endothelium damage induced by atherosclerosis leads
to the reduction in bioactivity of endothelial NO synthase with
subsequent impaired release of NO together with a local
enhanced degradation of NO by increased generation of reac-
tive oxygen species with subsequent cascade of oxidation-sen-
sitive mechanisms in the arterial wall. Therefore, a reduction in
NO activity contributes to a pro-inﬂammatory and prothrom-
botic milieu.19
Although the possible events that can initiate fatty streak
formation remain controversial, over the last few decades, a
plausible model linking lipids and inﬂammation to atherogen-
esis has emerged. LDL, which may be modiﬁed by oxidation,
glycation (in diabetes), aggregation, association with proteo-
glycans, or incorporation into immune complexes, is a major
cause of injury to the endothelium and underlying smooth
muscle. When LDL particles become trapped in an artery, they
can undergo progressive oxidation and be internalized by mac-
rophages by means of the scavenger receptors on the surfaces
of these cells. The internalization leads to the formation of
lipid peroxides and facilitates the accumulation of cholesterol
esters, resulting in the formation of foam cells.13
In most patients MIs occur as a result of erosion or uneven
thinning and rupture of the ﬁbrous cap, often at the shoulders
of the lesion where macrophages enter, accumulate, and are
activated and where apoptosis may occur. Degradation of
the ﬁbrous cap may result from elaboration of metalloprotein-
ases such as collagenases, elastases, and stromelysins. Acti-
vated T cells may stimulate metalloproteinase production by
macrophages in the lesions, which promotes plaque instability
and further implicates an immune response. These changes
may also be accompanied by the production of tissue factor
procoagulant and other hemostatic factors, further increasing
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onary or cerebral infarction, depending on the duration of the
thrombosis and the location of the associated vasoconstriction.
4. C-reactive protein (CRP)
4.1. Historical perspectives
CRP was ﬁrst discovered in 1930 by William Tillet and Tho-
mas Francis at the Rockefeller Institute for Medical Research,
in New York. In studying the blood of patients suffering from
acute Streptococcus pneumonia infection, it was found that the
sera of these patients formed a precipitin with an extract from
the streptococcal bacterium. The extract was originally labeled
Fraction C, and was later conﬁrmed as a polysaccharide.
Hence, as a result of its reactivity with the C polysaccharide
of the Streptococcus cell wall, the ‘substance’ in the sera was
named CRP.20 A decade later, Oswald Avery and Maclyn
McCarty-the research team who originally described the
‘‘transforming principle’’ and the concept that genes are made
of DNA also described CRP as an ‘‘acute-phase reactant’’ that
was increased in serum of patients suffering from a spectrum
of inﬂammatory stimuli, including myocarditis and the inﬂam-
mation associated with rheumatic fever.21–23Figure 1 PentamericEarly clues that this inﬂammatory biomarker might be
linked to atherothrombosis are evident in 2 case reports pre-
sented by Gunnar Lofstrom from the State Bacteriologic Lab-
oratory in Stockholm in 1943, in which increases in CRP
following AMI was described.24 In the mid 1950s, case series
presented by Irving Kroop and others indicated that CRP con-
centrations consistently increased after coronary ischemia and
myocardial necrosis.25 Despite these early ﬁndings, it was not
until the 1990s that cardiovascular interest in CRP was revital-
ized. In mid 1990s, immunoassays for CRP (hs-CRP), with
greater sensitivity than those previously routine uses, revealed
that increased CRP values, even within the range previously
considered normal, strongly predict future coronary events.
4.2. Structure of CRP
CRP belongs to the pentraxin family of calcium dependent
ligand-binding plasma proteins. The human CRP molecule is
composed of ﬁve identical non-glycosylated polypeptide sub-
units each containing 206 amino acid residues. The protomers
are non-covalently associated in an annular conﬁguration with
cyclic pentameric symmetry (Fig. 1). The pentraxin family,
named for its electron micrographic appearance from the
Greek penta (ﬁve) ragos (berries), is highly conserved in
evolution.26,27structure of CRP.27
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fold and bears on one face, the B or binding face, a pocket
which contains two calcium ions bound just 4 A˚ apart by coor-
dination with protein carboxylate and amide side chains
derived from loops that congregate on one face of the pro-
tomer core. These calcium atoms are essential for all physio-
logical ligand binding by CRP and also markedly stabilize
both the structure of the protomer and the integrity of the
native pentamer.28 Upon dissociation of its pentameric struc-
ture, CRP subunits undergo a spontaneous and irreversible
conformational change. The loss of the pentameric structure
of CRP results in modiﬁed or monomeric CRP (mCRP), which
is a naturally occurring form of CRP and it is a tissue-based
rather than a serum based molecule. mCRP is less soluble than
CRP and tends to aggregate, and it has been described to
induce mRNA of chemokines and the expression of adhesion
molecules in human cultured coronary artery ECs.29 In
human, the CRP gene is located on chromosome 1q23, in a
conserved genetic region, which codes for proteins important
for immune system as well as cell to cell communication.30
The major part of the CRP present in the plasma comes from
the liver, where the synthesis of CRP is mainly regulated by
interleukin-6 (IL-6), which in turn is up-regulated by other
inﬂammatory cytokines such as IL-1 and tumor necrosis factor
(TNF)-a. CRP also produced locally in atherosclerotic lesions
by SMCs lymphocytes and monocytic cells.29
4.3. Biological functions of CRP
Most functions of CRP are easily understood in the context of
the body’s defenses against infective agents. CRP provides the
ﬁrst line of defense of pathogen. Despite structural differences
with immunoglobulin molecule, CRP shares similar functional
properties with the immunoglobulins, such as, the ability to
promote agglutination, activation of the classical complement
pathway, bacterial capsular swelling, phagocytosis and precip-
itation of polycationic and polyanionic compounds.31 By anal-
ogy with antibodies, it is therefore possible that CRP might
contribute both to host defence against infection and enhance-
ment of inﬂammatory tissue damage. Other distinctive charac-
teristics of CRP are its binding speciﬁcities and its site of
synthesis which confer it to a new super family of proteins.
Phosphocholine is the natural ligand to which CRP binds with
highest afﬁnity and this key ligand is ubiquitous as the polar
head group of phosphatidlyl choline in cell membranes and
plasma lipoproteins. CRP does not bind to all materials con-
taining phosphocholine as the residues must be ‘available’ or
in an appropriate sterochemical conﬁguration. Thus CRP
binds to dead or damaged cells in which signiﬁcant amounts
of lysophosphatidyl choline are present, but not the surface
of living healthy cells.28 CRP also binds to a variety of other
autologous and extrinsic ligands, and it aggregates or precipi-
tates the cellular, particulate, or molecular structures bearing
these ligands. Autologous ligands include native and modiﬁed
plasma lipoproteins, damaged cell membranes, a number of
different phospholipids and related compounds, small nuclear
ribonucleoprotein particles, and apoptotic cells. Extrinsic
ligands include many glycan, phospholipid, and other constit-
uents of microorganisms, such as capsular and somatic compo-
nents of bacteria, fungi, and parasites, as well as plant
products.264.4. Circulating CRP levels
Surprisingly in view of the sensitivity, speed, and range of the
CRP response, subjects in the general population tend to have
stable CRP concentrations characteristic for each individual,
apart from occasional spikes presumably related to minor or
subclinical infections, inﬂammation, or trauma. In healthy
young adult volunteer blood donors, the median concentration
of CRP is 0.8 mg/L, the 90th centile is 3.0 mg/L, and the 99th
centile is 10 mg/L, but, following an acute-phase stimulus, val-
ues may increase from less than 50 lg/L to more than 500 mg/
L, that is, 10,000-fold.26 Importantly, acute-phase CRP values
show no relationship to fasting state or diurnal patterns and
have a long half-life. Liver failure impairs CRP production,
but no other intercurrent pathologies and very few drugs
reduce CRP values unless they also affect the underlying
pathology providing the acute-phase stimulus. After a stimu-
lus, within 6 h, plasma CRP levels increase above 5 mg/L
and reach the maximum within 48 h. CRP can rise up to
10,000-fold in acute inﬂammation, such as during infection.
After that, the level of CRP returns to very low reference val-
ues in plasma with the same speed. The half-life of CRP in
plasma is approximately 19 h and is constant during various
conditions in healthy and sick people. Therefore the only fac-
tor determining the level of CRP is its production speed, which
directly reﬂects the intensity of pathological process.30
4.5. Clinical utility of CRP
The attention focused on CRP reﬂects in part the fact that it
has assay characteristics conducive for clinical use, commer-
cially robust assay is available widespread, it is very stable in
serum or plasma with very marginal ﬂuctuations, more cost-
effective than the emerging risk markers and has been proven
to orchestrate atherosclerosis.32 It is easily measured, and stan-
dardized high-sensitivity immunoassays (detecting CRP con-
centrations <5 mg/L) provide similar results in fresh, stored,
or frozen plasma, reﬂecting the stability of the protein, which
has led CRP to emerge as a robust clinical marker. Moreover,
there is no diurnal variation and no signiﬁcant difference in the
distribution curve between men and women. Serum levels are
independent from age and ethnicity. All these factors make it
a relatively stable serum protein compared with many other
markers. In addition to in vitro and in vivo studies, a large
number of studies on the utility of CRP as a clinical marker
for CHD have been performed.8 Although CRP is a nonspe-
ciﬁc inﬂammatory marker, it is a strong independent predictor
for CHD risk and events. Epidemiological studies and clinical
trials have found that CRP is a strong independent predictor
of future CHD risk. Circulating CRP values correlate closely
with other markers of inﬂammation, some of which show sim-
ilar, albeit generally less signiﬁcant, predictive associations
with coronary events. Furthermore, the intrinsic biological
properties of CRP as an acute-phase reactant are especially
favorable for its use as a sensitive quantitative systemic read-
out of the acute-phase response. In contrast, none of the other
systemic markers of inﬂammation, whether upstream cytokine
mediators, other sensitive acute-phase proteins such as serum
amyloid A, negative acute-phase proteins such as albumin,
or cruder multifactorial measures such as erythrocyte sedimen-
tation rate or polymorph count, has such robust and desirable
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ior may sufﬁciently explain why it provides closer associations
and better predictions than other markers of inﬂammation.26
In addition to assessing future CHD risk in asymptotic
individuals, growing bodies of studies suggest that elevation
of hs-CRP levels predicts a poor cardiovascular prognosis.
CRP levels predict clinical outcomes in acute coronary syn-
dromes and may be used in conjunction with troponin I or T
levels to identify high-risk patients for more aggressive man-
agement with antiplatelet agents and statins. Similarly, in
patients undergoing percutaneous coronary interventions,
CRP levels may alert the interventional cardiologist for closer
monitoring of the patients or more aggressive management.
Components of the metabolic syndrome (i.e., central obesity,
increased plasma triglyceride concentrations, low plasma con-
centrations of HDL-C, hypertension, and increased concentra-
tions of blood glucose) correlate with increased plasma CRP
concentrations, and CRP measurement contributes to risk pre-
diction in individuals with the metabolic syndrome.33 Further-
more, CRP levels could be used to motivate patients to modify
their lifestyles more aggressively. Recent studies have shown
that losing weight, diet, exercise, cessation of smoking and
controlling diabetes also lower CRP levels. Thus, patients
can use their CRP levels as an inﬂammation ﬁtness score to
monitor improvement in their cardiovascular health. Some
medicines can also reduce CRP levels such as aspirin, statins,
thiazolidinediones, AT-converting enzyme inhibitors and
thienopyridines.34
Concerning hs-CRP level and CHD risk, a level of less than
1 mg/L indicates lower risk, a level between 1 and 3 mg/L indi-
cates moderate risk and a level higher than 3 mg/L indicates a
higher risk – that is simple enough. But the continuum extends
beyond that. The patients with the very highest levels of hs-
CRP; 5–10, 10–20, or even greater than 20 mg/L are, in fact,
at the very highest risk. These are not false positives. These
data help to explain why those with periodontal disease, arthri-
tis, and other systemic inﬂammatory disorders all have higher
vascular risk. Perhaps inﬂammation from any cause has an
adverse effect on the vascular endothelium.35 In current strat-
egies of global risk assessment, lipid testing is the only blood
test routinely recommended. However, CRP evaluation may
provide a simple and inexpensive method to improve global
risk prediction and compliance with preventive approaches,
when used as in addition to traditional lipid proﬁles.9
To improve cardiovascular risk stratiﬁcation in primary
prevention populations, an expert panel assembled by the Cen-
ters for Disease Control and Prevention and the American
Heart Association termed CRP an independent marker of car-
diovascular risk. The panel recommends the use of CRP as
part of global risk prediction in asymptomatic individuals, par-
ticularly those deemed at intermediate risk for CVD by tradi-
tional risk factors.36 The CRP concentration is thus a very
useful nonspeciﬁc biochemical marker of inﬂammation, mea-
surement of which contributes importantly to (a) screening
for organic disease, (b) monitoring of the response to treat-
ment of inﬂammation and infection {Serial measurements
reﬂects activity and response to treatment and can be used
for monitoring}, and (c) detection of intercurrent infection in
immuno-compromised individuals, and in the few speciﬁc dis-
eases characterized by modest or absent acute-phase responses.4.6. High sensitive CRP (hs-CRP)
The recent emphasis in cardiovascular medicine on ‘‘high-sen-
sitivity’’ or ‘‘highly sensitive’’ CRP, abbreviated as so-called
hs-CRP, seems to have created a false impression in some
quarters that this is somehow a different analyte from ‘‘con-
ventional’’ CRP. This is incorrect.26 It is very important to rec-
ognize that the analyte designated as hs-CRP is just CRP itself,
not anything new or different and in particular is not a novel
analyte with any special relationship to CHD. hs-CRP is the
same exquisitely sensitive and entirely nonspeciﬁc systemic
marker of infection, inﬂammation, tissue damage and/or
almost any form of adverse non-physiological stress as the
CRP, which has been extensively studied and used clinically
for over 75 years.28 Formerly, assays for CRP, using a poly-
clonal antibody had a sensitivity of about 5 mg/L. With these
assays, the level of CRP was detectable only during signiﬁcant
inﬂammation in most individuals. In the mid of 1990s, a new
method enzyme-linked immunosorbent assay (ELISA) was
established to evaluate the level of hs-CRP, which has much
higher sensitivity (to quantify CRP throughout its normal
range) then classic methods used previously.30 These lower lev-
els toward the upper end of normal reﬂect low-grade inﬂam-
mation and have a predictive value of future risk for CHD
events.37
4.7. Atherosclerosis, inﬂammation, and CRP
The possibility that CRP might have proatherogenic actions
was ﬁrst suggested in 1982 by the discovery of its speciﬁc bind-
ing to LDL and VLDL and was supported by its detection in
atherosclerotic plaque.28 Inﬂammatory mechanisms play a
central role in all phases of atherosclerosis, from the initial
recruitment of circulating leukocytes to the arterial wall to
the rupture of unstable plaques, which results in the clinical
manifestations of the disease. CRP may be involved in each
of these stages by direct inﬂuencing processes such as comple-
ment activation, apoptosis, vascular cell activation, monocyte
recruitment, lipid accumulation and thrombosis. CRP is one of
the substances present in the atherosclerotic lesion, more spe-
ciﬁcally in the vascular intima, where it co-localizes with
monocytes, monocyte-derived macrophages and lipoproteins.
This localization makes a direct contribution to the atheroscle-
rotic process.29 The direct pro-atherogenic effects of CRP
extend beyond the endothelium to the vascular smooth muscle.
CRP plays a pivotal role in many aspects of atherogenesis as
described brieﬂy below (Fig. 2):
 Activation of the classical pathway of the complement sys-
tem, through this action, CRP directly ampliﬁes and facili-
tates innate immunity, a process that has already been
associated with initiation and progression of CHD.29
 CRP increases LDL uptake into macrophages and enhances
the ability of macrophages to form foam cells. It also binds
the phosphocholine of oxidized LDL.
 CRP inhibits endothelial NO synthase expression in ECs.
NO has important anti-atherogenic effects, including
decreased platelet aggregation, vasoconstriction, and
smooth muscle cell proliferation.
Figure 2 Representation of CRP-mediated effects on atherosclerosis and CHD. LDL; low density lipoprotein, PAI; plasminogen
activator inhibitor.
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erful procoagulant, which can lead to disseminated intra-
vascular coagulation and ultimately to thrombosis during
inﬂammatory states.
 CRP upregulates the expression of adhesion molecules in
ECs that can attract monocytes to the site of injury.14
 CRP increases PAI-1 expression and activity. PAI-1 is a
protease inhibitor that regulates ﬁbrinolysis by inhibiting
tissue plasminogen activator. Increased PAI-1 indicates
lowered ﬁbrinolysis and thus leads to atherogenesis.32
 CRP also indirectly affects speciﬁc immune response, dur-
ing atherogenesis, through the increase of IL-12 production
from macrophages, with the subsequent induction of
CD4 + T lymphocytes differentiation and Interferon
gamma production.8
5. CRP and coronary heart disease
Elevated CRP has been associated with many non-communi-
cable diseases such as CHD, ischemic stroke, insulin resistance,
hypertension, metabolic syndrome and peripheral artery dis-
ease. The most extensively studied area is its role as a marker
and a maker of CHD. Several landmark large prospective clin-
ical case-control studies on middle-aged men (Physician’sHealth Study,38 Monitoring Trends and Determinants in Car-
diovascular Disease39), postmenopausal women (Women
Health Study40), and elderly men and women (Cardiovascular
Health Study Rural Health Promotion Project41) have identi-
ﬁed CRP as a strong, independent risk factor for CHD. In
some recent studies Arroyo Espliguero et al. 42 and Raposeiras
Roubı´n43 concluded that CRP is an independent predictor of
adverse cardiac events.
An association between sustained high values of CRP fol-
lowing AMI and adverse outcomes was ﬁrst reported in
198244 and subsequent large studies have shown that increased
peak and post-infarct CRP concentrations are signiﬁcantly
associated with increased incidence of cardiac complications
including heart failure and cardiac death, apparently indepen-
dently of other predictors28. Tissue necrosis is a potent acute-
phase stimulus, and following MI, there is a major CRP
response, the magnitude of which reﬂects the extent of myocar-
dial necrosis. Myocardial necrosis due to abrupt closure of cor-
onary artery, in case of AMI, leads to a systemic and regional
humoral and cellular inﬂammatory response aiming to pro-
mote the local myocardial healing process and scar formation.
In the early phase of MI, cytokines play an important cytopro-
tective role, mainly by reducing cell apoptosis. Pro-inﬂamma-
tory cytokines are the starting promoters of the humoral
post-MI healing process. They directly interfere with the myo-
96 A.K. Shrivastava et al.cardial contractility, the vascular endothelial function, and the
recruitment of other inﬂammatory cells. Plasma CRP
concentration increases following the cytokines activation in
the initial hours of MI. CRP binds to phosphocholine groups
of necrotic myocardial cell membranes, facilitating comple-
ment activation, and thus promoting further inﬂammatory
response, injury of myocardial cells, and expansion of
necrosis.45
In patients with ACS, an increase in the CRP level at
admission is associated with a poorer short-term and long-
term prognosis. The majority of authors concur in that the
admission CRP value reﬂects the baseline inﬂammatory status
of the patient; thus, patients with ACS and high CRP levels at
admission usually experience more cardiovascular complica-
tions during follow-up. Patients with ACS and higher CRP
may represent a group with hyper-responsiveness of the
inﬂammatory system, which might exaggerate the acute-phase
reaction and increase immune system activation, which may in
turn mediate myocardial damage and promote cardiac compli-
cations. This may be more pronounced in patients with non-
STEMI than in those with STEMI, due to a higher atheroscle-
rotic burden. As reported by several studies, elevated CRP lev-
els after MI are associated with adverse clinical outcome,
including cardiac rupture, heart failure, and cardiac death.
The higher the maximum CRP recorded, the more severe the
infarction suffered, the greater the likelihood of ventricular
remodeling, the lower the ejection fraction, and the greater
the risk of heart failure, heart rupture, and death.46
The likely mechanism of CRP pathogenicity is therefore
binding of abundant CRP to the ligands exposed in dead
and damaged cells, triggering substantial complement activa-
tion with release of chemotactic factors and opsonization of
cells in and around the lesion, leading to enhanced inﬁltration
by inﬂammatory cells and consequent bystander damage. The
terminal complement sequence may also directly kill cells
which would otherwise survive and the end result is death of
more myocardial tissue than would be killed by ischemia
alone.28
6. Conclusion
CHD is the leading cause of death and disability in developed
nations and is increasing rapidly in the developing world. Up
to half of all events associated with CHD are reported to occur
in apparently healthy individuals who have few or none of the
traditional risk factors, including dyslipidemia. As a result,
attention has increasingly turned to the role of other factors,
such as inﬂammation, in the development of atherosclerosis
and CHD. Recent observations suggest that the atherosclerotic
process is characterized by a low-grade inﬂammation altering
the endothelium of the coronary arteries and is associated with
an increase level in markers of inﬂammation. In an attempt to
improve global cardiovascular risk prediction, considerable
interest has focused on CRP. CRP is not only an excellent bio-
marker of inﬂammation, but it is also a direct participant in
atherogenesis. Many studies have demonstrated that increased
CRP concentrations are associated with an increased risk of
MI, stroke, peripheral arterial disease, and sudden cardiac
death. Unlike other markers of inﬂammation, CRP levels are
stable over long periods, have no diurnal variation, can be
measured inexpensively with available high-sensitivity assays,and have shown speciﬁcity in terms of predicting the risk of
cardiovascular disease. When combined with lipid screening,
CRP improves global risk prediction in patients who would
otherwise not be identiﬁed for primary prevention by lipid
assessment alone.7. Disclosure statement
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